Protein engineering techniques for antibody humanization.

[1]  R. Poljak,et al.  Three-dimensional structure of immunoglobulins. , 1979, Annual review of biochemistry.

[2]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[3]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[4]  M. Lascombe,et al.  Three-dimensional structure of antibodies. , 1988, Annual review of immunology.

[5]  M Levitt,et al.  A humanized antibody that binds to the interleukin 2 receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Winter,et al.  Phage antibodies: filamentous phage displaying antibody variable domains , 1990, Nature.

[7]  S. Spencer,et al.  Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  E. Padlan,et al.  A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. , 1991, Molecular immunology.

[9]  Y. Masuho,et al.  Phase I Study on Human Monoclonal Antibody Against Cytomegalovirus: Pharmacokinetics and Immunogenicity , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[10]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[11]  D R Burton,et al.  Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  K. Sandvig,et al.  Internalization and action of an immunotoxin containing mistletoe lectin A-chain. , 1991, Cancer research.

[13]  Geraldine Taylor,et al.  Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo , 1991, Bio/Technology.

[14]  J. Schlom,et al.  Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. , 1991, Cancer research.

[15]  E. Vitetta,et al.  Immunotoxins containing ricin or its A chain. , 1991, Seminars in cell biology.

[16]  Andrew D. Griffiths,et al.  By–Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling , 1992, Bio/Technology.

[17]  A. Brill,et al.  Intratumoral and whole-body distributions of C110 anti-carcinoembryonic antigen radioimmunotoxin after intraperitoneal and intravenous injection: a quantitative autoradiographic study. , 1992, Cancer research.

[18]  S. Carroll,et al.  Activity of recombinant mitogillin and mitogillin immunoconjugates. , 1992, The Journal of biological chemistry.

[19]  Mu‐Hsien Yu,et al.  Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma , 1992, International journal of cancer.

[20]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Schlom,et al.  Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[23]  I. Pastan,et al.  Recombinant toxins as novel therapeutic agents. , 1992, Annual review of biochemistry.

[24]  C. Barbas,et al.  Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Winter,et al.  Building Antibodies from their Genes , 1992, Immunological reviews.

[26]  L. Presta,et al.  X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. , 1993, Journal of molecular biology.

[27]  P Davies,et al.  Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences. , 1993, Journal of immunology.

[28]  J. Bye,et al.  Human anti‐self antibodies with high specificity from phage display libraries. , 1993, The EMBO journal.

[29]  L. Presta,et al.  Humanization of an antibody directed against IgE. , 1993, Journal of immunology.

[30]  Kevin Stuart Johnson,et al.  Human antibody engineering , 1993 .

[31]  J. Saunders,et al.  Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. , 1993, Immunology.

[32]  J. Saldanha,et al.  Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. , 1993, Protein engineering.

[33]  M. Lockyer,et al.  A humanized CD18 antibody can block function without cell destruction. , 1993, Journal of Immunology.

[34]  G. Winter,et al.  Engineering bispecific antibodies. , 1993, Current opinion in biotechnology.

[35]  J. Saldanha,et al.  Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. , 1993, Cancer Research.

[36]  T. Waldmann,et al.  Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta-chain that acts synergistically with humanized anti-TAC. , 1993, Journal of immunology.

[37]  C. Barbas,et al.  Selection of human anti-hapten antibodies from semisynthetic libraries. , 1993, Gene.

[38]  H. P. Fell,et al.  Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. , 1993, Cancer research.

[39]  M. Hurle,et al.  A role for destabilizing amino acid replacements in light-chain amyloidosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A R Rees,et al.  Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. , 1994, Journal of molecular biology.

[41]  T. Waldmann.  Lymphokine receptors: a target for immunotherapy of lymphomas. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  A R Rees,et al.  Humanization of murine monoclonal antibodies through variable domain resurfacing. , 1994, Proceedings of the National Academy of Sciences of the United States of America.